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Abstract
Devil Facial Tumour 1 (DFT1) is one of two transmissible neoplasms of Tasmanian devils
(Sarcophilus harrisii) predominantly affecting their facial regions. DFT1’s cellular origin is
that of Schwann cell lineage where lesions are evident macroscopically late in the disease.
Conversely, the pre-clinical timeframe from cellular transmission to appearance of DFT1
remains uncertain demonstrating the importance of an effective pre-clinical biomarker.
We show that ERBB3, a marker expressed normally by the developing neural crest and
Schwann cells, is immunohistohemically expressed by DFT1, therefore the potential of
ERBB3 as a biomarker was explored. Under the hypothesis that serum ERBB3 levels may
increase as DFT1 invades local and distant tissues our pilot study determined serum
ERBB3 levels in normal Tasmanian devils and Tasmanian devils with DFT1. Compared to
the baseline serum ERBB3 levels in unaffected Tasmanian devils, Tasmanian devils with
DFT1 showed significant elevation of serum ERBB3 levels. Interestingly Tasmanian devils
with cutaneous lymphoma (CL) also showed elevation of serum ERBB3 levels when com-
pared to the baseline serum levels of Tasmanian devils without DFT1. Thus, elevated
serum ERBB3 levels in otherwise healthy looking devils could predict possible DFT1 or CL
in captive or wild devil populations and would have implications on the management, welfare
and survival of Tasmanian devils. ERBB3 is also a therapeutic target and therefore the
potential exists to consider modes of administration that may eradicate DFT1 from the wild.
Introduction
The Tasmanian devil (Sarcophilus harrisii) belongs to the Dasyuridae family, it is a carnivorous
marsupial that is extinct on mainland Australia and now found only on the island of Tasmania.
Superficial dermal cutaneous lesions of wild Tasmanian devils can be found commonly in the
form of skin sores [1] and neoplasia [2]. Spontaneous neoplasms in captive Tasmanian devils
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including squamous cell carcinoma of the lip and gingiva, dermal lymphosarcoma [3], trichoe-
pithelioma, papilloma and keratoacanthoma [4] and a single devil with multiple unrelated
tumours involving internal organs in combination with skin [5] have been recorded, sugges-
tive of potential metastasis. Similar observations were made while reviewing Dasyurid archival
material at the Australian Registry of Wildlife Health [6] and recently, two captive female dev-
ils with pruritus and dermatitis were diagnosed with cutaneous T-cell lymphoma [7]. None of
the recorded neoplastic superficial lesions found in captive or wild Tasmanian devils appeared
to mimic the firm, flattened centrally ulcerated soft tissue lesions of DFT1 affected Tasmanian
devils [8].
Although the first evidence of DFT1 in wild populations occurred in 1996 when several
Tasmanian devils were photographed by Christo Baars in the north east of the state with facial
lesions. However, a tissue diagnosis was not obtained until 2001 [9]. Review of Tasmanian
devil archival slides submitted to the Animal Health Laboratory, DPIPWE, revealed a single
case in 1997 that was consistent with DFT1 [8, 10]. An emerging disease was finally recognised
in 2003 [10] and subsequent investigations revealed the tumour to be a transmissible allograft
being transferred from devil to devil via biting [11] with tumours tending to be located on the
face, lips and oral mucosa [8].The timeframe of the pre-clinical stage of DFTD1 remains
largely undetermined with observations ranging from 2–13 months [9, 12–15] but as little as 1
month has been recorded (Author unpublished observation, laboratory records, DPIPWE).
Immunohistochemical examination of DFT1 suggested a possible undifferentiated neuroen-
docrine tumour [16, 17] although subsequent molecular testing lead to the conclusion that
DFT1 is of Schwann cell origin [18]. Down-regulation mechanisms causing absence of major
histocompatibility complex (MHC) class 1 cell surface antigens is a major contributing factor
allowing the DFT1 allograft to evade the host devil’s immune system without rejection [19–
21]. Further cytogenetic and molecular techniques have identified four karyotypic strains that
are differentiated by a small number of identifiable rearrangements [22, 23]. As a consequence
of this cancer, wild populations of the Tasmanian devil have been significantly reduced in
Tasmania where the possibility of extinction either locally within 10–15 years [24, 25] or com-
pletely within 25–35 years [25] has been predicted. The impedance of this 2007 dire prediction
includes the adaption of wild Tasmanian devils to their life history change by precocial sexual
maturity [26] and through a strong collaborative scientific research and conservation manage-
ment framework devised by the Save the Tasmanian Devil Program (STDP) [27]. A second
transmissible tumour in Tasmanian devils, devil facial tumour 2 (DFT2), distinct from DFT1
has recently been reported [28] suggesting that the species may well be prone to transmissible
cancers, increasing the urgency of biomarker identification and therapeutic intervention.
ERBB3 is expressed in early embryonal development and plays an integral role in the devel-
opment of the neural crest and Schwann cells [29] regulating pathways that execute diverse cel-
lular functions including development, cell cycle, migration, survival, proliferation and
differentiation [30–34]. ERBB3 is a member of the Epidermal Growth Factor (EGF) family
representing a complex group of type 1 transmembrane receptor tyrosine kinase (RTK) with
differing ligands. The EGF family consists of four members and collectively the human epider-
mal growth factor receptor gene family members are designated EGFR/ERBB1/HER1,ERBB2/
HER2, ERBB3/HER3 and ERBB4/HER4 [35]. The extracellular domain (ECD) of ERBB recep-
tors has high structural homology although they bind selectively within a group of 11 peptide
growth factor members that includes Neuregulin 1 and 2 (NRG1/NRG2) both ERBB3 ligands.
[35–39]. Although the complex signalling network of ERBB receptors commonly activate the
mitogen activated protein kinase (MAPK) pathway and the phosphatidylinositide 3-Kinase
(PI3K) pathway [40–43], ERBB3 efficiently activates the PI3K pathway [44] due to the presence
of multiple p85 binding sites in its tyrosine kinase domain.
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Lateral signalling among ERBB’s is no more apparent than with receptors ERBB2 and
ERBB3 that must heterodimerise with other ERBB members to signal [40] as ERBB3 has a
ligand but impaired tyrosine kinase activity [45] and ERBB2 has no known ligand (orphan
receptor) but a functional kinase region [46]. Although ERBB3 has long been considered
impaired or termed a pseudo-kinase, it does have sufficient, although substantially reduced
[47], kinase activity. How ERBB3 is able to activate other ERBB family members with its weak
catalytic domain remained elusive until an allosteric mechanism termed an ‘asymmetric
dimer’ enabling trans-autophosphorylation was discovered [48].
ERBB2 and ERBB3 overexpression [49–51], cooperation in neoplastic transformation [44,
52–54] and loss of ERBB3 preventing the progressive transformation of ERBB2-over express-
ing tumours [55] reinforces ERBB3’s pivotal role in ERBB signalling. Early studies revealed
ERBB3 as a potential oncogene with overexpression due to possible increased transcription as
no gene amplification was observed [56, 57] although recently oncogenic mutations have been
reported [58] indicating either ERBB3 or its downstream components should represent a
potential target for therapy [59].
ERBB3 is upregulated in a number of human cancers such breast, colon, gastric, ovarian
and prostate [33, 60] but seldom reported in veterinary cancers [61–63] although it would
appear the instrumental role that ERBB3 may play in some veterinary tumours is yet to be elu-
cidated. DFT1’s immunohistochemical expression of ERBB3 led us to postulate that excess
extracellular domain (ECD) may circulate in the host’s plasma and present itself as a possible
candidate biomarker for DFT1. Literature reports five secreted alternative transcripts of
ERBB3 present in serum or interstitial fluid [64, 65] which can be detected utilising ELISA
methodology.
Our pilot study assessed serum ERBB3 for the for the first time in Tasmanian devils reveal-
ing that serum ERBB3 was substantially elevated in the serum of Tasmanian devils with DFT1
compared to those Tasmanian devils without DFT1. Interestingly, the inclusion of some Tas-
manian devils with CL in our pilot study revealed that ERBB3 may also be a biomarker for this
DFT1, although CL is clinically distinct from DFT1. We identify ERBB3 as a potential bio-
marker of DFT1 and highlight current literature supporting the therapeutic possibilities that
can be directed towards ERBB3 overexpressing tumours that may be helpful in the elimination
of DFT1 from the wild.
Materials and methods
Animal ethics statement
Serum and paraffin embedded tissue samples were collected by veterinary staff for the Save the
Tasmanian Devil Program (STDP) http://www.tassiedevil.com.au/tasdevil.nsf encompassing
health checks, field trapping trips, or autopsy due to animal welfare reasons. All samples were
accessed from the Animal Health Laboratory archive and did not require ethics approval.
Tasmanian devil ERBB3 pilot study
A pilot study of thirty-five Tasmanian devils differing in age, sex and geographic location were
selected (Table 1) to compare serum ERBB3 levels in clinically healthy Tasmanian devils
(CHD), devils with DFT1 and those with CL. The Fifteen CHD’S included both adults (n = 12)
and clinically healthy juvenile Tasmanian devils (CHJD, n = 3) 10 months of age. Adults
included free range captive (n = 5), captive (n = 3) and wild devils (n = 4). Clinically healthy
adults either had no visible disease (ND, n = 8) or had localised skin non-DFT1 dermatopathy
(CHDD, n = 4) consisting of two abscesses, a skin tag and localised dermatitis. Eight Tasma-
nian devils with clinical DFT1 and Twelve Tasmanian devils with CL. Tasmanian devils with
Devil facial tumour disease (DFTD)
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CL were included in the study as a severe skin condition recognised clinically but very distinct
from DFT1. All dermatopathies, DFT1 and CL were confirmed histologically by the Animal
Health Laboratory.
Table 1. Tasmanian devil pilot study individuals.
Devil Microchip Identification Laboratory accession Age (years) Sex (M/F) Geographic location Clinical status
1 982000190997443 13/3712 1 F Freycinet a CHD
2 982000123211124 13/3683 3 F Freycinet a CHD
3 982009104963600 13/3680 4 M Freycinet a CHD
4 982009104860765 13/3713 4 M Freycinet a CHD
5 982000123130282 13/3716 2 M Freycinet a CHD
6 982009105111670 09/4200 3 F West Pencil Pine b CHD
7 982009105849999 09/3957 2 M Tullah b CHD
8 985154000001063 09/1051 1 M Cressy c CHD
9 982009104269684 08/1805 2 M Narawntapu b CHDD
10 982009106039877 10/0156 2 M Dunalley b CHDD
11 982009104236464 08/0798 1 F Taroona c CHDD
12 982009104357109 09/2009 4 F Fern Tree c CHDD
13 985154000001151 09/0451 <1 M Mt Pleasant d CHJD
14 985154000001142 09/0449 <1 F Mt Pleasant d CHJD
15 985154000001130 09/0448 <1 M Mt Pleasant d CHJD
16 982009104841875 12/2065 6 F West Pencil Pine b DFT1
17 982009106034139 11/0767 2 F Dunalley b DFT1
18 982009104719592 12/0820 4 F West Pencil Pine b DFT1
19 982000000122095 12/2095 2 F Upper Natone b DFT1
20 982000123128645 11/3917 2 M Hamilton b DFT1
21 982000123216973 11/3918 1 F Hamilton b DFT1
22 982000123209814 11/4493 2 M Waratah b DFT1
23 000000000130406 13/0406 2 F Mangalore b DFT1
24 NC 11/0650 7 F Mole Creek c CL
25 985120016024404 11/4290 8 F Mt Pleasant c CL
26 982009106314654 10/4001 8 M Taranna c CL
27 982009106585887 10/3765 5 F Calder b CL
28 982009104789818 14/0034 6 F Cressy c CL
29 NC 08/4048 4 F Circular Head b CL
30 982009100786171 09/0402 6 F Mt Pleasant c CL
31 982009101694833 10/1013 6 F Richmond c CL
32 982009104910854 13/0518 6 F Cressy c CL
33 NC 09/3035 5 F South Riana b CL
34 NC 11/1615 6 F Mole Creek c CL
35 982009104873582 13/3714 4 F Freycineta CL*
NC not microchipped, CHD clinically healthy devil, CHDD clinically healthy devil with dermatopathy, CHJD clinically healthy juvenile devil, DFT1 devil facial
tumour 1, CL cutaneous lymphoma
a Free range enclosure
b Wild devil
c Captive devil
d captive juvenile
* no tissue diagnosis.
https://doi.org/10.1371/journal.pone.0177919.t001
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Tasmanian devil serum sample and collection
Blood samples from Tasmanian devils (Table 1) were collected by wildlife veterinarians
through jugular venepuncture, whilst the animals were restrained by a trained field officer.
Ten millilitres of blood was collected in sterile serum separation tubes, stored on ice for trans-
port to the laboratories, centrifuged and serum removed for archival storage at -20˚C. Serum
samples were retrieved from the frozen archive and thawed at room temperature immediately
before analysis.
Histology
Tasmanian Devil tissues were fixed in 10% Neutral Buffered Formaldehyde (Confix, ACFC,
Australian Biostain, Traralgon, Victoria, Australia) for 24 hours and selected tissues were cas-
setted and processed overnight using a standard 15 hour overnight procedure in the TP1050
tissue processor (Leica Microsystems, Wetzlar, Germany). Tissues were orientated on the
EG1160 (Leica), embedded in paraffin wax (Surgipath Paraplast, 39601006, Leica) and sec-
tioned at 3 microns using Leica RM2245 microtome and adhered to microscope slides (Menzel
Glaser, Braunschweig, Germany) for 20 minutes at 60˚C. Sections were deparaffinised, rehy-
drated and stained using Jung autostainer XL (Leica) for Haematoxylin (Harris’ Haematoxylin,
AHHNA, Australian Biostain) and Eosin, dehydrated cleared and mounted in CV Mount
(Leica, 046430011).
Immunohistochemistry
Archival Tasmanian devil tissues and tumours were sectioned at 3 microns, floated onto
Superfrost plus slides (Menzel Glaser) and subjected to standard deparaffinisation and rehy-
dration techniques using an automated stainer (Leica). Antigen retrieval in tissue sections was
conducted in citrate buffer at pH 6.0 (Reveal Decloaker, Biocare Medical, California, USA) at
120˚C for 8 minutes using a Pascal pressure chamber (Dako, Glostrup, Denmark) then cooled
to 20˚C. Endogenous peroxidase activity was quenched using 3% hydrogen peroxide (Ajax
Finechem, Sydney, Australia, 260) in methanol (Ajax, 723) for 30 minutes. Detection of pri-
mary antibodies was achieved using Mach1 Universal HRP-Polymer detection kit (Biocare
Medical, California, USA, M1U539GL10). Protein block (Background Sniper BS966L10) was
applied for 20 minutes prior to application of primary antibodies. Monoclonal rabbit anti-
human ERBB3 (Abcam, clone SP71, ab93739, internal region) was diluted 1:50 with antibody
diluent (Dako, S0809) and applied to both devil tumour and normal devil control tissues at
room temperature for 30 minutes. Negative control was omission of primary antibody with
buffer substitution. Universal HRP-polymer was applied for 30 minutes (MRH538L10) fol-
lowed by 1 drop of Betazoid DAB Chromogen 3,3 Diaminobenzidine (BDB900G) in 1ml
of substrate buffer (DB900) applied for 4 minutes. Tris buffered saline (Biocare Medical,
TWB945) was used to rinse between all steps. Slides were rinsed, stained with Carazzi’s Hae-
matoxylin for 5 minutes, washed for 3 minute in tap water, dehydrated, cleared and mounted
in CV mount. Sections were viewed under light microscopy using Olympus BX41 (Olympus
corporation, Tokyo, Japan) and selected areas were photographed using an Olympus digital
camera (DP20).
ERBB3 ELISA assay
Serum ERBB3 levels were measured using the RayBio anti-human ERBB3 ELISA Kit
(ELH-ERBB3, RayBiotech Inc, GA, USA) according to manufacturer’s instructions. Briefly,
serum samples were diluted 1/5 in Assay Diluent A and 100 uL of standard or diluted sample
Devil facial tumour disease (DFTD)
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were added in duplicate to wells of a 96 well assay plate and incubated for 24 hrs at 4˚C. The
supernatant was removed and wells were washed 4 times with 300 uL of 1X wash solution
using an Immunowash 1575 (BioRad Laboratories, CA, USA). One hundred microliters of
prepared biotinylated anti-ERBB3 was added to each well and the assay plate incubated for 1
hour at room temperature. The assay plate was washed as described after which 100 uL of pre-
pared HRP-streptavadin conjugate was added to each well and the assay plate incubated for 45
minutes at RT. The assay plate was again washed as described and 100 uL of TMP substrate
was added and the plate incubated for 30 minutes at room temperature in the dark, after
which 50 uL of stop reagent was added to each well. The absorbance of each well was measured
at 450 nm using a Tecan Infinite M200 microplate reader (Tecan, Salzburg, AUT).
Data analysis
The ELISA standard curve was plotted using Prism v5 (GraphPad, CA, USA) and results for
each serum interpolated and corrected for dilution. The significance of differences in serum
ERBB3 between groups was determined using a Kruskal-Wallis test with Dunn’s Multiple
Comparison utilizing Prism v5 (GraphPad, CA, USA).
Results
Histology and Immunohistochemstry
DFT1 histology (Fig 1A) and Haematoxylin and Eosin demonstrates small round cells with
indistinct cell membranes arranged in cords and packets. ERBB3 IHC on average revealed mod-
erate to strong expression in 75% of cells in both primary and secondary DFT1 tumours in cyto-
genetically determined strains 1 to 5 of DFT1. Typical granular cytoplasmic expression (Fig 1B)
demonstrated by DFT1 strain 3 cells with small and large aggregates noted. Higher magnifica-
tion (Fig 1C) shows accumulation in and around vacuolar structures within the cytoplasm. In
sections of devil skin and subcutous (Fig 1E), peripheral nerve was seldom positive for ERBB3
(red arrow) in keeping with downregulation of ERBB3 in the adult in contrast to DFT1 ERBB3
expression (black arrow). ERBB3 expression was noted in Tasmanian devil lymphoid follicle
(Fig 1F) where cytoplasmic expression of ERBB3 is present in both T (germinal centre) and B
(mantle) cells. Devils with CL were not included in the ERBB3 immunohistochemical staining.
Trigeminal nerve section (Fig 1I) showed ERBB3 expression in nerve bodies (black arrow) and
occasional ERBB3 expression in the adaxonal area (red arrows) but generally small myelinated
nerves were negative. Positive control included devil bowel (Fig 1G) which exhibited a similar
expression pattern to human ERBB3 and negative controls DFT1 (Fig 1D), bowel (Fig 1H) and
Trigeminal nerve (Fig 1J). The monoclonal rabbit anti-human ERBB3 clone SP71 is a synthetic
peptide corresponding to an internal sequence of Human ERBB3. Although the exact sequence
is a proprietary secret ERBB3 sequence alignment between Human and Tasmanian devil in this
region has high homology (S1 Fig. ERBB3 Orthologue protein alignment).
Serum ERBB3 in Tasmanian devils
Serum ERBB3 levels are shown in Table 2 and graphically in Fig 2. Serum ERBB3 in the Fifteen
Tasmanian devils without neoplasia (devils 1–15 includes CHD,CHDD and CHJD) ranged
from <30–663 pg/ml with a median of 32 pg/mL (30–220; interquartile range). Serum ERBB3
levels in the eight Tasmanian devils (devils 16–23) with clinical DFT1 ranged from 766–18,254
pg/ml with median of 3051 pg/mL (1060–10879; interquartile range. In the twelve Tasmanian
devils with cutaneous lymphoma (devils 24–35) serum ERBB3 levels ranged from <30–20,021
pg/ml with a median of 1485 pg/mL (289–7901; interquartile range).
Devil facial tumour disease (DFTD)
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Discussion
ERBB3 in devils without DFT1
Fifteen Tasmanian devils without neoplasia (twelve adults either wild caught, free range or
captive enclosures and three captive juveniles encompassing CHD, CHDD and CHJD) were
studied with an average serum ERBB3 of 32 pg/ml. Collectively, CHD Tasmanian devils serum
ERBB3 levels ranged from<30–663 pg/ml which could be considered representative of the ref-
erence range for Tasmanian devils. Wild caught devils 6 and 7 were unremarkable and had
serum ERBB3 levels <30 pg/ml however devil 9 (220 pg/ml) and devil 10 (92 pg/ml) both
recorded skin abscesses. The ERBB3 levels in the CHDD group (devils 9, 10, 11 and 12) ranged
from<30–220 pg/ml all had a small isolated dermatopathy such as abscess (devil 9), pyogranu-
loma (devil 10), skin tag with associated inflammation (devil 11) and small focus of dermatitis
(devil 12) all recorded a low serum ERBB3 levels of<92 pg/ml. The CHJD (devils 13, 14 and
15) approximately 10 months old had an unremarkable clinical history that indicated serum
was collected for a health check only, reflected in the low serum ERBB3 level of<30 pg/ml.
Fig 1. DFT1 staining and skin manifestation. (A) Haematoxylin and Eosin stained DFT1 x40, (B) ERBB3
Immunohistochemical expression in DFT1 strain 3 x40, (C) ERBB3 immunohistochemical expression in DFT1
strain 3 x100, (D) DFT1 negative control, (E) Tasmanian devil skin and subcutis section with peripheral nerve
(red arrow) and DFT1 (black arrow) x10, (F) Tasmanian devil lymph node ERBB3 expression lymphoid follicle
x20, (G) Tasmanian devil bowel ERBB3 positive control x40, (H) ERBB3 IHC negative control bowel, (I)
trigeminal nerve shows ERBB3 positive nerve body (black arrow) and occasional adaxonal ERBB3 positivity
(red arrows) x40, (J) ERBB3 IHC negative control trigeminal nerve, (K) Tasmanian Devil gross appearance of
DFT1. Photo credit: DPIPWE archive, (L) Tasmanian devil gross appearance cutaneous lymphoma. Photo
credit DPIPWE archive.
https://doi.org/10.1371/journal.pone.0177919.g001
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Further assessment of data and clinical history (Table 2) revealed that four out of five Tas-
manian devils from the Freycinet free range enclosure (devils 1–5) had higher serum ERBB3
ranging from 155–663 pg/ml compared to most other clinically healthy devils having serum
ERBB3 levels <30 pg/ml. The Freycinet free range enclosure (FRE) consists of a 22 Hectare
natural reserve that creates living conditions that are more similar to the wild than traditional
captive conditions. The structure is fenced completely enclosing an insurance population of
Table 2. Tasmanian devil serum ERBB3 and clinical history.
Devil Serum Erbb3
(pg/ml)
Weight
(Kg)
Serum transit
(days)
clinical history BCS (0–
5)
DFT1
strain
DFT1 1o No
(range cm)
Mets
No
1 155 N/A 1 CHD, NAD
2 663 N/A 1 CHD, Localised alopecia
3 207 OW 1 CHD, Multiple punctures
4 313 N/A 1 CHD, Multiple punctures
5 291 N/A 1 CHD, Multiple minor wounds
6 <30 N/A 1 CHD, Few wounds, lactating
7 <30 N/A 2 CHD, N/A
8 <30 6 1 CHD, Great condition
9 220 10.5 1 CHDD, Abscess/scab on face
10 92 N/A 2 CHDD, Abscess left neck.
11 <30 4.7 1 CHDD, Skin tag on left ear
12 <30 N/A 1 CHDD, Dermatitis upper flank
13 <30 4.2 1 CHJD, Health check
14 32 3.4 1 CHJD, Health check
15 <30 4.6 1 CHJD, Health check.
16 18,254 N/A 1 DFT1, weak 2 2 2 (1.0–2.5) 3
17 999 6.1 3 DFT1, Reared 4 young 2 3 4 (1.0–1.5) 5
18 11,090 4.8 1 DFT1, Poor body condition 1–2 1 4 (2.0–3.0) 1
19 1903 3.7 1 DFT1, Emaciated disorientated 0 1 2 (1.6–5.2) 10
20 10,247 10 3 DFT1, Multiple lesions 3 2 4 (1.0–2.0) 2
21 1241 5 3 DFT1, Poor body condition 2.5 2 3 (1.0–1.5) 1
22 4198 9.3 4 DFT1, Advanced DFT1 2 4 7 (1.0–2.5) 0
23 766 N/A 1 DFT1, Emaciated 2 1 7 (1.0–4.7) 1
24 4383 6.7 1 CL, Generalised alopecia N/A
25 <30 8.2 1 CL, cutaneous plaques chest N/A
26 <30 8.0 1 CL, percutaneous plaque N/A
27 2008 5.9 1 CL, Skin lesions N/A
28 837 5.9 1 CL, Alopecia Poor
29 9703 5.3 1 CL, Generalised alopecia Poor
30 2403 8.2 1 CL, Alopecia ventrally N/A
31 536 7.4 1 CL, Alopecia left neck, pouch N/A
32 962 6.7 1 CL, Alopecia ventrally N/A
33 11,837 5.4 1 CL, Widespread alopecia 1–2
34 207 5.7 1 CL, Multifocal dermatitis, cutaneous lump
(acanthoma)
Poor
35 20,021 N/A 1 CL, Multifocal alopecia N/A
N/A not available, NAD no abnormality detected, OW over weight, BCS—body condition score, DFT1 strain–cytogenetically determined strain, DFT1 1o
No–number and size of primary tumours recorded, Mets No—number of metastasis recorded, CHD clinically healthy devil, CHDD clinically healthy devil
with dermatopathy, CHJD clinically healthy juvenile devil, DFT1 devil facial tumour 1, CL cutaneous lymphoma
https://doi.org/10.1371/journal.pone.0177919.t002
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healthy devils with density caped to approximately one devil per hectare. This type of enclo-
sure allows devils the opportunity to compete at feeding and breeding times and bite wounds
are therefore common (David Schaap, personal communication). In contrast, captive devils
are housed in small enclosures that measure approximately 100 m2 containing capped at one
devil per 100 m2.
We noted that skin injuries were commonly recorded although no abnormality was noted
for devil 1, alopecia bilaterally around the hind limbs and flank was present on one mother
due to her 3 pouch young (devil 2) and multiple puncture wounds were present on the remain-
der (devils 3, 4 and 5). Given that these devils were otherwise clinically healthy it would suggest
that skin wounds caused by biting may contribute to some elevation in the serum ERBB3 of
Tasmanian devils. There is also the possibility that simply being a Tasmanian devil living in a
free range enclosure as opposed to wild populations may in itself be contributory to elevation
in serum ERBB3 due to more frequent devil-devil engagement. Our results indicate that Tas-
manian devils without injuries or an isolated skin lesion have serum ERBB3 levels <30 pg/ml
whereas Tasmanian devils with multiple injuries or large abscesses have serum ERBB3 levels
ranging from 92–663 pg/ml. Together, these results suggest that cancer-free Tasmanian devils
have a serum ERBB3 range of<30–663 pg/ml.
ERBB3 in devils with DFT1
All devils with DFT1 were wild caught and all subjected to field autopsy with most serum sam-
ples reaching the laboratory within one to three days. We assessed the available clinical history
(Table 2) including animal weight, body condition score (BCS 1–5) where 1 = emaciated,
2 = moderately thin, 3 = average, 4 = good and 5 = obese (Sarah Peck, personal communica-
tion), number of primary and metastatic DFT1’s and cytogenetic strain ensuring the consider-
ation of any factors that may contribute to the ERBB3 range in DFT1 affected Tasmanian
Fig 2. Serum ERBB3 levels in Tasmanian devils. Serum ERBB3 levels were measured by ELISA in
clinically healthy Tasmanian devils CHD (n = 11), clinically healthy Tasmanian devils with dermatopathy
CHDD (n = 4), clinically diagnosed DFT1 (n = 8) and those with cutaneous lymphoma CL (n = 12). Horizontal
dashed line indicates the limit of detection of the ELISA assay at 30 pg/mL. Results of individual devils are
shown with the median and interquartile range identified by the whiskers. Significance testing using a Kruskal-
Wallis test with Dunn’s Multiple Comparison Testing shown with * representing p < 0.05.
https://doi.org/10.1371/journal.pone.0177919.g002
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devils. No correlation was established between levels of ERBB3 and extent of DFT1 when com-
paring the number and size of primary DFT1 lesions and any metastatic disease (see Table 2).
For example, the devil with the highest serum ERBB3 of 18,254 pg/ml (devil 16), had 2 primary
lesions with 3 metastases whereas the lowest serum ERBB3 of 766 pg/ml (devil 23) had seven
primary DFT1 lesions and one metastasis. No correlation was established between serum
ERBB3 levels and the BCS as most were low (BCS 1–2) with only one devil (devil 20) having a
BCS of three out of five, indicating average body condition. Cytogenetic strain did not appear
to correlate to serum ERBB3 levels and reflects the immunohistochemical findings that ERBB3
expression was present in all cytogenetic strains of DFT1. Our results indicate that Tasmanian
devils with DFT1 have elevated serum ERBB3 levels compared to clinically healthy Tasmanian
devils ranging from 766–18,254 pg/ml and that the extent of DFT1 does not readily correlate
directly with the serum ERBB3 levels. Further investigations beyond the pilot study encom-
passing a larger study group of Tasmanian devils with advanced DFT1 and metastases would
be necessary to establish any relationship with serum ERBB3 and the extent of DFT1.
ERBB3 in devils with cutaneous lymphoma
We included Tasmanian devils with cutaneous lymphoma (CL) in the study for two reasons.
Firstly, they were non-DFT1 devils with a severe skin condition that can affect the facial
regions and secondly, the disease presentation of alopecia, excoriation and thickened plaques
is distinct from DFT1 (Fig 1E and 1F). Our results revealed that some Tasmanian devils with
CL had elevated serum ERBB3 levels, a result that was most unexpected. Although ERBB3
immunohistochemistry on Tasmanian devils with CL was beyond the scope of this research,
ERBB3 Immunohistochemical staining of Tasmanian devil lymph node (Fig 1D) did reveal
ERBB3 expression in the lymphoid follicle where cytoplasmic expression of ERBB3 is present
in both T (germinal centre) and B (mantle) cells. CL devils were in the older age bracket rang-
ing from 4–8 years where the maximum age of a wild devil would be considered 5–6 years
(Sarah Peck, personal communication). Bodyweights ranging from 5.4–8.2 Kg compared to
the mean weight of 6.6Kg for female and 8.3Kg for male [66] shows possible female under-
weight wild devils and overweight captive devils. Age or weight did not appear to correlate to
the broad range of serum ERBB3 of 30–20,021 pg/ml. Interestingly, 11 of the 12 devils with CL
were female. We noted that devils with widespread alopecia (devils 24, 29, 33 and 35), did
exhibit increased serum ERBB3 levels ranging from 4383–20,021 pg/ml, suggesting that the
severity of CL manifesting clinically as widespread alopecia may contribute to increased serum
ERBB3 levels. Together, the elevated serum ERBB3 results in devils with CL is unlikely to
cause confusion with DFT1 as CL tends to affects devils in the older age group and the clinical
signs of CL are also distinct from DFT1 in established disease. Additionally, if elevated serum
ERBB3 levels in Tasmanian devils indicative of CL could be established (pre-clinical) this
would improve the healthy captive breeding populations of Tasmanian devils to ensure sur-
vival of the species by excluding these devils from this program.
Potential source of serum ERBB3
The capture and detection of antibody in our ELISA assay is selective for the extracellular
domain (ECD) of transmembrane ERBB3 in serum or plasma, thus ERBB3’s ECD is cleaved
and shed from the plasma membrane would be a natural assumption. In contrast the ERBB3
receptor is internalised, although very slowly, for negative regulation and inactivation [67–71]
utilising pathways such as caveolin or micropinocytosis and clathrin-and caveolin indepen-
dent pathways [72, 73]. ERBB3 has also been shown to be endocytosed independent of phos-
phorylation and without ligand in clathrin-dependent manner [74]. ERBB3 is degraded by
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proteasomes catalysed by two E3 ubiquitin ligases; NRDP1 (Neuregulin Receptor Degradation
Protein -1) [75], now known as RNF41 (Ring Finger 41, E3 Ubiquitin Protein Ligase) [76–78],
and NEDD4 (Neural Cell Precursor Expressed, Developmentally Down-regulated 4, E3 Ubiqui-
tin Protein Ligase) [79] that regulate steady-state ERBB3 levels influencing NRG1 signalling.
Defective internalisation, recycling and degradation of cell surface proteins and ligands is
an emerging feature of cancer [80]. It is therefore conceivable that DFT1 is subjected to the
same dysregulation and inefficient degradation and recycling resulting in over expression of
ERBB3 receptor at the plasma membrane and subsequent detectable levels of serum ERBB3.
While dysregulated endocytosis, deregulation and recycling may theoretically account for
excess ERBB3 ECD detectable in serum, secreted isoforms of ERBB3 must also be considered
as an alternative explanation for the presence of excess ERBB3.
As well as functional transmembrane forms, secreted soluble forms of Epidermal Growth
Factor Receptors have been well documented for ERBB1 [81–84], ERBB2 [85–88] and ERBB4
[89–91]. Alternative transcripts for ERBB3 resulting in naturally occurring soluble truncated
isoforms including a 1.4 kb transcript of ERBB3 in gastric cancer cell lines [64] and an addi-
tional four novel transcripts (1.6, 1.7, 2.1, and 2.3kb) from ovarian cancer cell lines [65] en-
couraged researchers to identify these secreted isoforms of ERBB3 in Prostate [92–95], liver
[96], breast [97, 98] and squamous cell carcinoma [99]. ERBB3 isoforms have also been ex-
pressed intracellularly in breast cancer cell lines [97] as well as in the nucleus of Schwann cells
[100, 101], prostate [102–104] and breast [105, 106]. Secreted ERBB3 isoform p85 has been
shown to inhibit the action of its ligand Neuregulin [98, 107], nuclear translocations act as co-
transcriptional activators [108], possible post-translation modification and the tumour micro-
environment are instructive to serum ERBB3 secretion from the cell [96] and functions yet to
be determined.
The antigenic peptide used for this assay is located within the N-terminal domain of the full
length ERBB3 protein. Full length ERBB3 translates into a 180 kDa protein whereas ERBB3
transcripts, created by intron read through and alternative polyadenylation signals result in
serum ERBB3 isoforms translating into various proteins ranging in size from 22–75 kDa [109].
Secreted isoforms such as ERBB3-S (1.4kb, 140aa homologous to the N terminus and a 43aa
unique carboxy terminal sequence) equates to approximately half of domain I, p50 (1.6kb,
351aa homologous to the N terminus and a 30aa unique carboxy terminal sequence) equates
to domain I, II and some of domain III, p45 (1.7kb, 310aa homologous to the N terminus and
a 2aa unique carboxy terminal sequence) equates to domain I, II and some of domain III, p85
(2.1kb, 519aa homologous to the N terminus and a 24aa unique carboxy terminal sequence)
equates to domain I, II,III and some of domain IV, p75 (2.3kb, 474aa homologous to the N ter-
minus and a 41aa unique carboxy terminal sequence) equates to domain I, II and III [64, 65,
109] ERBB3 isoforms have been detected by a number of methods such as immunoprecipita-
tion [65, 97, 107], immunohistochemistry [92] and ELISA [94–96]. Isoforms that have been
detected using ELISA assays include p45 sERBB3 utilising a capture antibody of sequence
aa20-643 (detection antibody sequence was not recorded) [94, 95] and 40-50kDa secreted iso-
forms (possible p45/p50) utilising both capture and detection antibodies with a sequence aa20-
643 [96]. The Raybio ELISA kit utilised in our research uses a capture and detection antibody
of sequence aa20-643 (personal communication Raybio) which accounts for most of the extra-
cellular domain of ERBB3 and therefore would be able to capture and detect both truncated
isoforms as well as the transmembrane ERBB3.
The correlation of serum levels with disease severity and progression would be the founda-
tion of a good biomarker [96] as well; the expected biomarker should be in excess when com-
pared to clinically healthy individuals [81] or possess additional qualities such as theranostic
and tertiary prevention [84]. The use of serum ERBB’s as an indicator of human cancer
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appears useful however, its prognostic and theranostic value remains controversial and contin-
ued investigations will be required [81–96, 99]. The development of a diagnostic test for pre-
clinical DFT1 would assist in the field operations if individuals could be identified before they
become infectious[110], therefore application of serum ERBB3 as a diagnostic biomarker of
DFT1 has great potential. The simplicity of the ELISA Serum ERBB3 methodology is easily
incorporated into routine batch testing or rapid turnaround of results for urgent cases if
required. Our research suggests that serum ERBB3 can be used as a biomarker for DFT1 and
CL irrespective of transmembrane or truncated forms being detected in the serum of affected
animals and therefore the potential of serum ERBB3 as a biomarker of early DFT1 detection
should be explored.
Schwann cell neoplasms
ERBB3 is crucial to the sequential transition from precursor to immature and finally mature
Schwann cells where ERBB3 is down-regulated as myelination proceeds [111]. The adult
peripheral nervous system requires maintenance when injured and the NRG1/ERBB system is
crucial to Schwann cell dedifferentiation, proliferation, and subsequent regeneration and
remyelination where ERBB3 and NRG1 is upregulated and only switched off after axon re-
generation illustrating the plasticity of the Schwann cell [112–114]. Peripheral nerve sheath
tumours [neurofibroma, malignant peripheral nerve sheath tumours (MPNST)] and schwan-
noma arise from the Schwann cell lineage and can be genetically characterised as Neurofibro-
mas (either dermal or plexiform) and MPNST’s [Neurofibromatosis 1 (NF1)], or Schwannomas
[Neurofibromatosis 2 (NF2)], Schwannomatosis and Carney complex type 1. Although distinct
characterisation of these complex diseases is possible, frequent overlapping features make diag-
nosis difficult and must also include other tumours with a Schwannian component such as
Neuroblastic and Granular Cell Tumours [reviewed in [115–119]]. Veterinary Schwann cell
neoplasms have been recorded [120–124] although ERBB3 expression in Schwann cell neoplasia
has not previously been reported in veterinary literature. ERBB3 receptor has been expressed in
human Schwann cell neoplasms including neurofibroma, MPNST, Schwannoma, neuroblastic
[125, 126] and ganglioneuroma (GN) tumours [127]. Interestingly, the down regulation of
MHC class 1 and 2 molecules in a MPNST cell line [128] contrasting normal expression [129,
130] may indeed be similar to the MHC class 1 downregulation of DFT1 [19–21] resulting in
defective antigen processing and presentation of the malignant Schwann cell neoplasm.
ERBB3 as a therapeutic target
Despite evidence for multiple resistance mechanisms for existing therapeutic targeting of
ERBB1/2 [131–141] numerous researchers have over the last decade explored the potential of
ERBB3 as a therapeutic target [reviewed in [33, 60, 142–150]] using monoclonal antibodies
[57, 151–176], histone inhibitors [177], TKI [178], surrobodies [179], locked nucleic acid
(LNA)-based ERBB3 antisense oligonucleotide (ASO) [180], peptide mimics and vaccine
[181], anti-anginal drug [182] and disulphide disrupting agent [183].
However, managing wildlife disease is considerably more difficult than human disease
because of limited data, the effect of the disease on the host and the transmission of disease
within a dynamic population makes it difficult to model [184]. Previous efforts to eradicate
DFT1 from wild populations by selective culling has proven unsuccessful because of the fre-
quency-dependent transmission of DFT1 and the latency period [110, 184, 185]. TKI’s as a
therapeutic approach may be limited due primarlily to the early observation that kinase region
of ERBB3 had substantialy reduced activity, however cancer immunotherapy broadly catego-
rised as passive (including monoclonal antibodies, Cytokines, adoptive cell transfer) or active
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(including therapeutic cancer vaccine, immune checkpoint inhibitors) remains optimistic
[186–191]. Many of these successful human immunotherapeutics do hold similar promise in
veterinary medicine [192–194] however, drug administration to wild Tasmanian devils is very
different from the clinical setting of human and companion animals and therefore treatments
such as adoptive cell transfer would be difficult to implement. The fact that DFT1 expresses
tumour associated antigens (TAA’s) such as ERBB3 invites the application of monoclonal anti-
bodies and therapeutic cancer vaccines as prospective treatments. The passive administration
of monoclonal antibodies to ERBB3 primarily focused on blocking receptor epitopes are still
experimental [57, 151–176] and any humanised anti-ERBB3 would certainly have to be become
species specific (devil anti-ERBB3) to prevent adverse immunologic reactions [195]. Very few
monoclonal antibodies have been developed in veterinary oncology although two caninised anti-
bodies anti-ERBB1 [196] and anti-CD20 [197] show promise. Therapeutic cancer vaccination
modalities applicable to wildlife include antigen delivery vaccines that utilise inactivated cancer
cells (autologous or allogenic) or peptide vaccines that mimic antigen sequences. Results using
an inactivated cancer cell vaccine trial (allogenic DFT1 cell line) are eagerly awaited (http://
www.utas.edu.au/news/2015/10/16/19-world-first-trial-of-tasmanian-devil-vaccine-begins-in-
the-wild/). Confidence that immunisation can be successful stems from research showing that
Tasmanian devils have a competent immune system [21, 198–200] and can produce cytotoxic
antibodies [14, 201]. An alternative antigen presentation modality to cancer cell vaccine is a
peptide vaccine, where single or multiple amino acid sequences (long or short) representing a
defined antigen is combined with adjuvant to elicit an immune response [202]. Development of
just a single ERBB3 peptide vaccine can be found in the literature [181] however, peptide vac-
cines targeting ERBB1 [203, 204], ERBB2 [205–207] or both ERBB1/2 [208] including monoclo-
nal antibody against tyrosine related protein 1 (TRP-1) and altered peptide sequence to gp100
for mouse melanoma [209] all show promise. Overcoming self-tolerance is a major hurdle,
one such strategy is the use of Xenoantigens, that is the exact same antigen but from a different
species that has considerable sequence homology, differing only by several amino acids which
appear to the host as altered epitopes or as “altered self” and therefore tolerance can be broken
causing a T-cell response against the endogenous self-antigen [210]. Veterinary xenogeneic vac-
cinations include a DNA plasmid vaccine encoding human Tyrosinase (TYR) [211] the only vet-
erinary therapeutic tumour vaccine licensed by the United States department of Agriculture
(USDA) for the use of oral and digital melanoma, now marketed as OnceptTM.
Recent investigations reveal that the tumour microenvironment of metastatic DFT1
expressed B7-H1 and DFT1 cell lines could upregulate B7-H1[212]. Immune-suppressive
tumour microenvironment created by tumour cells that escape ‘immunoediting’ allowing
tumour growth and proliferation [213] where certain checkpoint pathways will be used advan-
tageously by tumour cells to confer immune resistance [214]. Hence, checkpoint blockades
(monoclonal antibodies) targeting Programmed Cell Death 1 (PD1 or PDCD1) and its ligand
PD-L1 (B7-H1) and Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) are now attractive thera-
peutical targets [215]. Recent views consider cancer immunotherapy invaluable although a sin-
gle treatment mode may be suitable for some cases, more combinatorial approach will be
needed for others [216, 217].
Our research has highlighted ERBB3 as a potential therapeutic target however treatment of
Tasmanian devils with DFT1 with therapeutic regimes such as chemotherapy and radiother-
apy are impractical. However, a combinatorial approach using therapeutic cancer vaccines
including inactivated allogenic DFT1 cancer vaccine, ERBB3 monoclonal antibody, ERBB3
Peptide or xenogeneic vaccine in combination with anti-immune checkpoint blockade therapy
would be easier to implement in the field as well as providing a sustained immunological
response against DFT1.
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Conclusion
ERBB3 had previously avoided scrutiny due to its kinase inactivity; however, ERBB3 has now
been the subject of intense investigation over the past decade and is now recognised as a potent
partner of the epidermal growth receptor family. ERBB3 upregulation during developmental,
dedifferentiation and regenerative processes encapsulates the Schwann cell’s inherent plasticity
and imparts certain characteristics of malignant transformation advantageous to transmission
of DFT1. Our pilot study has shown for the first time that ERBB3 is consistently expressed
immunohistochemically and that ERBB3 is also elevated in the serum of Tasmanian devils
with advanced DFT1 and cutaneous lymphoma. Therefore, our research indicates that serum
ERBB3 has the potential to be employed as a biomarker of DFT1 or CL in Tasmanian devils to
assist conservationists in the management and welfare of Tasmanian devils and species sur-
vival. The simplicity of the ELISA Serum ERBB3 methodology is easily incorporated into rou-
tine laboratory batch testing and equally applied to include rapid turnaround of results for
urgent cases. Extension of this research is necessary to include greater numbers of healthy Tas-
manian devils both with and without visible injuries, devils with large and small DFT1 lesions
as well as pre-clinical DFT1. This will firmly establish the normal reference range for serum
ERBB3 from which potential pre-clinical DFT1 may be identified. In addition, ERBB3 is now
recognised as a therapeutic target and therefore the potential exists to consider modes of
administration in addition to existing whole cell vaccination such as ERBB3 monoclonal anti-
body, peptide or xenogeneic vaccines including checkpoint inhibitors. A combinatorial immu-
notherapeutic approach will enhance cytotoxic destruction, provide long term immunity from
DFT1 and therefore eradicate this transmissible tumour from the wild.
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